Inquiry Basket
CAS No.: 721945-30-8
Cat No.: BADC-00685
4.5 
Daunorubicinol is a drug-linker conjugate for ADC with potent antitumor activity by using Aur0101 (DNA Topoisomerase II inhibitor), linked via the ADC linker.
Structure of 721945-30-8
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
MCC-Modified Daunorubicinol represents a significant advancement in the field of antibody-drug conjugates (ADCs) for targeted cancer therapy. By harnessing the unique properties of daunorubicinol and enhancing its delivery through a strategically engineered ADC linker, this compound aims to improve the efficacy and safety profile of cancer treatments. The MCC (Maleimide Compound Conjugation) modification is integral in optimizing the conjugation efficiency and stability of the drug, thereby offering a superior therapeutic index compared to traditional chemotherapeutic agents
The primary application of MCC-Modified Daunorubicinol lies in its ability to selectively target and destroy malignant cells while minimizing collateral damage to healthy tissues. This targeting is achieved through the precise conjugation of the drug to antibodies that recognize and bind specific antigens expressed on the surface of cancer cells. Once bound, the conjugate is internalized into the cancer cell, where it releases daunorubicinol, a potent inhibitor of DNA Topoisomerase II, disrupting DNA replication and triggering apoptosis. This targeted approach significantly reduces systemic toxicity and enhances antitumor efficacy, making MCC-Modified Daunorubicinol a promising candidate for treating various aggressive cancers that overexpress these antigens
In addition to its direct antitumor effects, MCC-Modified Daunorubicinol has potential applications in overcoming multidrug resistance—a major hurdle in cancer therapy. The highly specific targeting mechanism allows this ADC to bypass traditional drug efflux pathways employed by cancer cells to resist treatment. By delivering daunorubicinol directly into the cancer cell, MCC-Modified Daunorubicinol can effectively counteract resistance mechanisms, thereby restoring the sensitivity of cancer cells to therapy. This makes the drug particularly useful in treating relapsed or refractory cancers, where existing treatments have failed
Furthermore, MCC-Modified Daunorubicinol is being explored for use in combination therapies, where it can be paired with other therapeutic agents to enhance anticancer effects. The precision targeting capability of MCC-Modified Daunorubicinol allows for synergistic interactions when used alongside traditional therapies such as radiation or other chemotherapeutic agents. Such combinations can lead to improved patient outcomes by maximizing tumor cell kill rates while reducing the required dosage of each agent, thereby decreasing the risk of adverse side effects
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-01360 | Daunorubicin citrate | 1884557-85-0 | |
| BADC-00042 | Daunorubicin | 20830-81-3 | |
| BADC-00039 | Doxorubicin | 23214-92-8 | |
| BADC-00041 | Daunorubicin hydrochloride | 23541-50-6 |
What is MCC-Modified Daunorubicinol?
MCC-Modified Daunorubicinol is a derivative of the anthracycline daunorubicin, modified for conjugation in ADCs. It maintains cytotoxic properties while enabling selective delivery via monoclonal antibodies.
12/1/2023
Could you kindly advise how MCC-Modified Daunorubicinol functions in ADCs?
Once conjugated to an antibody, MCC-Modified Daunorubicinol is internalized by target cells. The linker is cleaved intracellularly, releasing the daunorubicinol derivative to exert cytotoxic effects on tumor cells.
1/12/2019
Could you kindly explain what types of research benefit from MCC-Modified Daunorubicinol?
This compound is used in oncology ADC research, providing a versatile payload for preclinical studies aimed at evaluating therapeutic efficacy against various cancer models.
8/12/2022
Could you please let me know if MCC-Modified Daunorubicinol is suitable for different antibody formats?
Yes, MCC-Modified Daunorubicinol can be conjugated to IgG or other antibody formats, facilitating the development of ADCs with specific targeting properties for diverse antigens.
28/8/2022
Good morning! What safety precautions should be followed for MCC-Modified Daunorubicinol?
Handling MCC-Modified Daunorubicinol requires strict laboratory safety measures, including protective clothing, containment strategies, and careful disposal of cytotoxic waste to avoid exposure.
18/9/2020
— Dr. David Miller, Senior ADC Researcher (USA)
MCC-Modified Daunorubicinol arrived with exceptional purity, supporting precise ADC conjugation.
8/12/2022
— Dr. Alice Johnson, Medicinal Chemist (UK)
Batch-to-batch consistency of MCC-Modified Daunorubicinol allowed reproducible in vitro assays.
18/9/2020
— Dr. Felix Schneider, Biochemist (Germany)
Fast delivery and detailed QC documentation for MCC-Modified Daunorubicinol facilitated workflow efficiency.
28/8/2022
— Dr. Sophie Wilson, Senior Scientist (Canada)
Reliable MCC-Modified Daunorubicinol quality ensured accurate cytotoxicity measurements.
12/1/2023
— Dr. Robert Hughes, Research Fellow (USA)
High-purity MCC-Modified Daunorubicinol supported multiple ADC experiments seamlessly.
— Dr. Emma Laurent, Pharmacology Scientist (France)
Professional guidance combined with consistent MCC-Modified Daunorubicinol quality accelerated project timelines.
1/12/2019
MCC-Modified Daunorubicinol
Required fields are marked with *
MCC-Modified Daunorubicinol
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
